Programme Thesis
The EIC Accelerator funds single deep-tech companies (not consortia) to bring breakthrough innovations to market, providing up to €2.5M in non-dilutive grant funding and up to €15M in equity, with a focus on high-risk, visionary research and commercial scale-up. It exists to bridge the funding gap for European startups and SMEs developing cutting-edge technologies with significant market potential.
Selection Criteria
- Eligibility: Must be a startup or SME incorporated in an EU Member State or Horizon Europe associated country; the applicant must be a company (not an individual or unincorporated venture).
- Innovation: The project must represent a significant technological breakthrough or deep-tech innovation with clear novelty and high-risk/high-reward potential.
- Market potential: Strong commercial viability, clear market need, and scalable business model; evidence of customer interest or market traction.
- Team: Capable and committed team with relevant expertise and ability to execute the project.
- Impact: Potential for economic growth, job creation, and alignment with EU strategic priorities (e.g., digital, health, green transition).
- Evaluation process: Three-step process: (1) short online application (form-based), (2) full proposal with pitch deck and video, (3) face-to-face interview with EIC jury; scoring based on the above criteria, with a focus on breakthrough potential and commercial strategy.
Past Winners / Cohort Profiles
Past EIC Accelerator winners include deep-tech startups across sectors like AI, biotech, clean tech, and advanced manufacturing. Typical archetypes: a small team (often 2-10 people) with a patented or patentable technology, a clear product-market fit, and a compelling pitch. Named examples are not provided on the page, but known winners include companies like IQM Quantum Computers, Nium, and others in the EIC portfolio.
Ideal Candidate Fingerprint
The platonic ideal applicant is an incorporated EU-based startup (SME) with a breakthrough deep-tech innovation, a strong IP position, a credible business plan, and a team with both technical and commercial expertise. They have early traction (e.g., pilot customers, letters of intent) and can articulate a clear path to market and scale, with a compelling pitch that convinces the EIC jury of the technology's disruptive potential.
Recommended Framing
For Eniola Olutogun, the strongest angle is to leverage the TOPOLOGIX venture (ESM-2 protein-language-model delta-embeddings plus Morgan/ECFP fingerprints for drug-resistance prediction) as the core technology, given its direct alignment with EIC's deep-tech focus in AI-driven drug discovery and its demonstrated performance (AUROC 0.804 on Platinum benchmark) that beats structure-based baselines. The framing should emphasize the commercial potential of TOPOLOGIX as a standalone product (e.g., a SaaS platform for pharmaceutical R&D), while highlighting Eniola's unique multi-domain expertise (pharmacist, computational modeler, software engineer) and the Africa/Nigeria angle for global health impact. However, the venture must be incorporated as an EU-based company (e.g., in Germany, given the M.Sc. enrollment) before applying, and the application should focus on the business case, not the academic research lines.
Watch Out
The venture is not yet incorporated, which is a prerequisite for EIC Accelerator (must be an SME registered in an EU Member State). The applicant is an independent researcher, not a startup founder with a business track record; the application will need to demonstrate commercial acumen and a viable business model. The research lines are academic and pre-commercial; EIC Accelerator funds market-ready innovations, so the application must pivot from research to product. Also, the applicant's location (Île-de-France) is mentioned in the notes, but the applicant profile indicates Germany (HPI/Potsdam) – ensure the company is incorporated in an eligible EU country.
Research History
2026-08-04 19:56 · medium confidence
2026-07-30 08:44 · medium confidence